On-Demand Webinars

Transitioning from Injectable to Oral Drug Delivery

Analytical Services
CDMO
Drug Product
Formulation Development
Oral Solid Dose
Pharma Development
sterile manufacturing

Innovative Integrated Strategies for Oral and Injectable Drug Products

Alcami participated in Drug Development and Delivery’s 2026 Drug Development and Delivery Day, where Katie Schlipp, President of Laboratory Operations, delivered a rapid-fire session on the formulation, analytical, and manufacturing strategies driving successful transitions from injectable to oral drug delivery.

This industry event brought together development and manufacturing leaders to address the scientific and operational challenges shaping modern drug product programs. During her session, Katie explored how integrated approaches across formulation science, analytical development, and manufacturing can compress timelines, reduce development risk, and support the growing demand for patient-friendly oral delivery options.

Hosted by

Featured Speaker

Katie Schlipp President of Laboratory Operations, Alcami

Why Watch

  • Rapid-fire format — high-impact insights in a concise, accessible session
  • Practical strategies for navigating the injectable-to-oral transition
  • Expert perspective on integrating formulation, analytical, and manufacturing decisions early
  • Relevant for R&D scientists, formulation teams, and CMC leaders evaluating development approaches

Access the Recording Now Fill out the form to watch instantly and learn how Alcami’s integrated expertise supports complex oral and injectable drug product programs from development through delivery.

"*" indicates required fields

Lookup*
You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.*
Summary

What You’ll Learn:

  • Key formulation and analytical considerations when transitioning from injectable to oral delivery
  • How early integration of manufacturing strategy reduces risk and accelerates development timelines
  • The role of a full-service CDMO in supporting complex drug programs across both dosage forms
  • Practical approaches to balancing scientific rigor with speed-to-clinic and speed-to-market goals